Insider Selling: Natera, Inc. (NASDAQ:NTRA) CFO Sells 946 Shares of Stock

Natera, Inc. (NASDAQ:NTRA) CFO Michael Burkes Brophy sold 946 shares of the firm’s stock in a transaction that occurred on Friday, January 24th. The shares were sold at an average price of $171.98, for a total transaction of $162,693.08. Following the completion of the sale, the chief financial officer now owns 109,474 shares of the company’s stock, valued at approximately $18,827,338.52. This trade represents a 0.86 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Michael Burkes Brophy also recently made the following trade(s):

• On Wednesday, January 22nd, Michael Burkes Brophy sold 25,931 shares of Natera stock. The stock was sold at an average price of $164.97, for a total value of $4,277,837.07.
• On Thursday, October 31st, Michael Burkes Brophy sold 1,866 shares of Natera stock. The shares were sold at an average price of $126.45, for a total transaction of $235,955.70.
• On Monday, October 28th, Michael Burkes Brophy sold 1,238 shares of Natera stock. The stock was sold at an average price of $118.21, for a total value of $146,343.98.

Natera Trading Down 2.5 %

Shares of NASDAQ NTRA traded down $4.21 during midday trading on Friday, reaching $167.61. 909,104 shares of the stock were exchanged, compared to its average volume of 1,393,352. Natera, Inc. has a 12 month low of $62.96 and a 12 month high of $183.00. The company has a debt-to-equity ratio of 0.33, a current ratio of 4.39 and a quick ratio of 4.23. The business has a 50-day simple moving average of $166.20 and a two-hundred day simple moving average of $136.07. The company has a market capitalization of $22.13 billion, a price-to-earnings ratio of -95.23 and a beta of 1.65.

Natera (NASDAQ:NTRA) last announced its quarterly earnings data on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share for the quarter, beating the consensus estimate of ($0.57) by $0.31. The company had revenue of $439.80 million during the quarter, compared to analysts’ expectations of $361.43 million. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. Natera’s revenue for the quarter was up 63.9% compared to the same quarter last year. During the same quarter last year, the company earned ($0.95) EPS. As a group, equities research analysts expect that Natera, Inc. will post -1.56 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the company. Sanford C. Bernstein increased their target price on Natera from $160.00 to $200.00 and gave the company an “outperform” rating in a research report on Friday, January 10th. JPMorgan Chase & Co. boosted their target price on shares of Natera from $160.00 to $200.00 and gave the stock an “overweight” rating in a research report on Friday, December 13th. Piper Sandler lifted their price target on Natera from $150.00 to $200.00 and gave the company an “overweight” rating in a report on Monday, November 18th. Morgan Stanley boosted their price target on Natera from $132.00 to $176.00 and gave the company an “overweight” rating in a research note on Thursday, November 14th. Finally, Guggenheim boosted their target price on Natera from $170.00 to $200.00 and gave the stock a “buy” rating in a report on Friday, January 17th. One equities research analyst has rated the stock with a sell rating and seventeen have issued a buy rating to the company’s stock. According to data from MarketBeat, Natera has an average rating of “Moderate Buy” and an average target price of $162.94.

Hedge Funds Weigh In On Natera

A number of institutional investors have recently bought and sold shares of NTRA. Chartwell Investment Partners LLC raised its holdings in Natera by 37.9% in the 3rd quarter. Chartwell Investment Partners LLC now owns 41,302 shares of the medical research company’s stock valued at $5,243,000 after acquiring an additional 11,362 shares during the period. Cerity Partners LLC grew its holdings in Natera by 27.0% in the 3rd quarter. Cerity Partners LLC now owns 86,144 shares of the medical research company’s stock valued at $10,936,000 after buying an additional 18,316 shares in the last quarter. Wilmington Savings Fund Society FSB acquired a new stake in shares of Natera during the third quarter worth $385,000. Everence Capital Management Inc. bought a new stake in shares of Natera in the fourth quarter valued at about $573,000. Finally, First Turn Management LLC acquired a new stake in Natera in the 3rd quarter worth about $19,760,000. Institutional investors and hedge funds own 99.90% of the company’s stock.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.